Management of Post-myocardial Infarction Patients with Left Ventricular Systolic Dysfunction
Overview
Authors
Affiliations
After a myocardial infarction (MI), patients are at risk for reinfarction, heart failure (HF), and sudden death. This risk is much higher in patients with left ventricular systolic dysfunction (LVSD). Although post-MI patients with LVSD have an even greater risk of mortality and morbidity, they had been generally excluded from clinical trials. This article reviews recent clinical trials that included post-MI patients with LVSD with or without signs and symptoms of HF. These trials have defined the benefits of pharmacologic management and device therapy in patients who survive an MI in the presence of LVSD.
Vazquez-Sanchez S, Blasco A, Fernandez-Corredoira P, Cantolla P, Mercado-Garcia E, Rodriguez-Sanchez E J Pathol. 2025; 265(3):342-356.
PMID: 39815421 PMC: 11794962. DOI: 10.1002/path.6388.
Jang Y, Kim H, Na S, Hong M, Yoon J, Lee H Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338297 PMC: 11434789. DOI: 10.3390/ph17091132.
Krittanawong C, Rizwan A, Khawaja M, Newman N, Escobar J, Virk H Curr Cardiol Rep. 2024; 26(9):919-933.
PMID: 38985226 DOI: 10.1007/s11886-024-02090-x.
Mechanism of heart failure after myocardial infarction.
Jiang H, Fang T, Cheng Z J Int Med Res. 2023; 51(10):3000605231202573.
PMID: 37818767 PMC: 10566288. DOI: 10.1177/03000605231202573.
Maries L, Moatar A, Chis A, Marian C, Luca C, Sirbu I Biomedicines. 2023; 11(8).
PMID: 37626785 PMC: 10452683. DOI: 10.3390/biomedicines11082289.